Preemptive Pharmacogenetic-Guided Metoprolol Management for Postoperative Atrial Fibrillation in Cardiac Surgery: The Preemptive Pharmacogenetic-Guided Metoprolol Management for Atrial Fibrillation in Cardiac Surgery Pilot Trial

被引:1
作者
Staben, Rae [1 ]
Vnencak-Jones, Cindy L. [2 ]
Shi, Yaping [3 ]
Shotwell, Matthew S. [1 ,3 ]
Absi, Tarek [4 ]
Shah, Ashish S. [4 ]
Wanderer, Jonathan P. [1 ,5 ]
Beller, Marc [6 ]
Kertai, Miklos D. [1 ,7 ]
机构
[1] Vanderbilt Univ, Med Ctr, Dept Anesthesiol, Nashville, TN USA
[2] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN USA
[3] Vanderbilt Univ, Med Ctr, Dept Biostat, Nashville, TN USA
[4] Vanderbilt Univ, Med Ctr, Dept Cardiac Surg, Nashville, TN USA
[5] Vanderbilt Univ, Med Ctr, Dept Biomed Informat, Nashville, TN USA
[6] Vanderbilt Univ, Med Ctr, Ctr Precis Med, Nashville, TN USA
[7] Vanderbilt Univ, Med Ctr, Dept Anesthesiol, 1211 21st Ave South,MAB 526, Nashville, TN 37212 USA
关键词
atrial fibrillation; cardiac surgery; beta-blockers; pharmacogenetic testing; CYP2D6; GENOTYPE; METABOLIZERS; ASSOCIATION; PHENOTYPE; RISK;
D O I
10.1053/j.jvca.2023.06.017
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Objectives: To test the hypothesis that implementation of a cytochrome P-450 2D6 (CYP2D6) genotype guided perioperative metoprolol administration will reduce the risk of postoperative atrial fibrillation (AF), the authors conducted the Preemptive Pharmacogenetic-Guided Metoprolol Management for Atrial Fibrillation in Cardiac Surgery pilot study. Design: Clinical pilot trial. Setting: Single academic center. Participants: Seventy-three cardiac surgery patients. Measurements and Main Results: Patients were classified as normal, intermediate, poor, or ultrarapid metabolizers after testing for their CYP2D6 genotype. A clinical decision support tool in the electronic health record advised providers on CYP2D6 genotype guided metoprolol dosing. Using historical data, the Bayesian method was used to compare the incidence of postoperative AF in patients with altered metabolizer status to the reference incidence. A logistic regression analysis was performed to study the association between the metabolizer status and postoperative AF while controlling for the Multicenter Study of Perioperative Ischemia AF Risk Index. Of the 73 patients, 30% (n = 22) developed postoperative AF; 89% (n = 65) were normal metabolizers; 11% (n = 8) were poor/intermediate metabolizers; and there were no ultrarapid metabolizer patients identified. The estimated rate of postoperative AF in patients with altered metabolizer status was 30% (95% CI 8%-60%), compared with the historical reference incidence (27%). In the risk-adjusted analysis, there was insufficient evidence to conclude that modifying metoprolol dosing based on poor/intermediate metabolizer status was associated significantly with the odds of postoperative AF (odds ratio 0.82, 95% CI 0.15-4.55, p = 0.82). Conclusions: A CYP2D6 genotype guided metoprolol management was not associated with a reduction of postoperative AF after cardiac surgery. (c) 2023 Published by Elsevier Inc.
引用
收藏
页码:1974 / 1982
页数:9
相关论文
共 36 条
  • [11] CYP2D6 Genotype-guided Metoprolol Therapy in Cardiac Surgery Patients: Rationale and Design of the Pharmacogenetic-guided Metoprolol Management for Postoperative Atrial Fibrillation in Cardiac Surgery (PREEMPTIVE) Pilot Study
    Dunham, Wills C.
    Weinger, Matthew B.
    Slagle, Jason
    Pretorius, Mias
    Shah, Ashish S.
    Absi, Tarek S.
    Shotwell, Matthew S.
    Beller, Marc
    Thomas, Erica
    Vnencak-Jones, Cindy L.
    Freundlich, Robert E.
    Wanderer, Jonathan P.
    Sandberg, Warren S.
    Kertai, Miklos D.
    [J]. JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA, 2020, 34 (01) : 20 - 28
  • [12] Mechanisms, prevention, and treatment of atrial fibrillation after cardiac surgery
    Echahidi, Najmeddine
    Pibarot, Philippe
    O'Hara, Gilles
    Mathieu, Patrick
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (08) : 793 - 801
  • [13] Pharmacogenomic biomarker information in drug labels approved by the United States Food and Drug Administration: Prevalence of related drug use
    Frueh, Felix W.
    Amur, Shashi
    Mummaneni, Padmaja
    Epstein, Robert S.
    Aubert, Ronald E.
    DeLuca, Teresa M.
    Verbrugge, Robert R.
    Burckart, Gilbert J.
    Lesko, Lawrence J.
    [J]. PHARMACOTHERAPY, 2008, 28 (08): : 992 - 998
  • [14] 2011 ACCF/AHA/HRS Focused Updates Incorporated into the ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation
    Fuster, Valentin
    Ryden, Lars E.
    Cannom, Davis S.
    Crijns, Harry J.
    Curtis, Anne B.
    Ellenbogen, Kenneth A.
    Halperin, Jonathan L.
    Kay, G. Neal
    Le Huezey, Jean-Yves
    Lowe, James E.
    Olsson, S. Bertil
    Prystowsky, Eric N.
    Tamargo, Juan Luis
    Wann, L. Samuel
    [J]. CIRCULATION, 2011, 123 (10) : E269 - E367
  • [15] Prediction of CYP2D6 phenotype from genotype across world populations
    Gaedigk, Andrea
    Sangkuhl, Katrin
    Whirl-Carrillo, Michelle
    Klein, Teri
    Leeder, J. Steven
    [J]. GENETICS IN MEDICINE, 2017, 19 (01) : 69 - 76
  • [16] New-onset postoperative atrial fibrillation after heart surgery
    Gudbjartsson, Tomas
    Helgadottir, Solveig
    Sigurdsson, Martin Ingi
    Taha, Amar
    Jeppsson, Anders
    Christensen, Thomas Decker
    Riber, Lars Peter Schoedt
    [J]. ACTA ANAESTHESIOLOGICA SCANDINAVICA, 2020, 64 (02) : 145 - 155
  • [17] Impact of CYP2D6 Polymorphisms on Clinical Efficacy and Tolerability of Metoprolol Tartrate
    Hamadeh, I. S.
    Langaee, T. Y.
    Dwivedi, R.
    Garcia, S.
    Burkley, B. M.
    Skaar, T. C.
    Chapman, A. B.
    Gums, J. G.
    Turner, S. T.
    Gong, Y.
    Cooper-DeHoff, R. M.
    Johnson, J. A.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 96 (02) : 175 - 181
  • [18] OXIDATION PHENOTYPE - A MAJOR DETERMINANT OF METOPROLOL METABOLISM AND RESPONSE
    LENNARD, MS
    SILAS, JH
    FREESTONE, S
    RAMSAY, LE
    TUCKER, GT
    WOODS, HF
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1982, 307 (25) : 1558 - 1560
  • [19] A Tutorial for Pharmacogenomics Implementation Through End-to-End Clinical Decision Support Based on Ten Years of Experience from PREDICT
    Liu, Michelle
    Vnencak-Jones, Cindy L.
    Roland, Bartholomew P.
    Gatto, Cheryl L.
    Mathe, Janos L.
    Just, Shari L.
    Peterson, Josh F.
    Van Driest, Sara L.
    Weitkamp, Asli O.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 109 (01) : 101 - 115
  • [20] Modeling continuous response variables using ordinal regression
    Liu, Qi
    Shepherd, Bryan E.
    Li, Chun
    Harrell, Frank E., Jr.
    [J]. STATISTICS IN MEDICINE, 2017, 36 (27) : 4316 - 4335